ReIGNITE Therapeutics
PrivateLast Round
Accelerator
Apr 1, 2025
Total Funding Raised
$1.2M
Company Overview
ReIGNITE Therapeutics is a biotechnology company that leverages directed evolution to engineer next-generation viral vectors for oncolytic immunotherapies and gene therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ReIGNITE Therapeutics Comparables
Compare ReIGNITE Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Adze Biotechnology | 81% | |
| VacV Biotherapeutics | 80% | |
| KaliVir Immunotherapeutics | 79% | |
ReIGNITE Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Accelerator | Apr 1, 2025 | ||||
| Corporate Funding | Mar 1, 2024 |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 1, 2025
$200K round led by SkyDeck
- Mar 1, 2024
$1M raised from 4DMT.
ReIGNITE Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about ReIGNITE Therapeutics's valuation, stock price, and market status.